Name Eligible Study sites More information
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (VALOR) 18 Years to 74 Years (Adult, Older Adult) California, Colorado, Florida, New York, Texas More Details; Priovant Therapeutics, Inc.; NCT05437263; Clinical Trial Administrator (646) 402-6892
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA) 18 Years and older (Adult, Older Adult) United States More Details; Argenx; NCT05523167; Contact: Sabine Coppieters, MD 857-350-4834
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM). 18 Years and older

 

Canada, Czechia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, United Kingdom, United States More Details; Janssen Research & Development, LLC; NCT05379634
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis 18 years of age or older at the time of signing the informed consent. Body weight ≥ 30 kilograms at the time of Screening. Male or female. see more details Sites in US, Italy, Korea and Spain More details; Alexion Pharmaceuticals, Inc; 855-752-2356; NCT04999020
Abatacept (Orencia) Active DM/PM/NM/JDM (over 18), overlap 78 sites in US, Australia, S. America, Asia, Europe More details; BMS StudyConnect; NCT02971683
Sodium thiosulfate for treatment of calcinosis associated with juvenile and adult dermatomyositis DM and JDM with calcinosis National Institutes of Health, Bethesda, MD More details; Adam Schiffenbauer 301-451-6270; NCT03267277
IgPro20 (Hizentra) Active DM, ADM (over 18) 94 sites in US, Australia, Japan, Argentina, Mexico, Europe, Ukraine, Russia More details; Trial Registration Coordinator 610-878-4000; NCT04044690